ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 教員研究業績
  2. 実践社会薬学研究室
  3. 原著論文

Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.

https://gifu-pu.repo.nii.ac.jp/records/14838
https://gifu-pu.repo.nii.ac.jp/records/14838
cb89decf-9ad8-45b1-a665-4c519ca29134
Item type 研究室原著論文(1)
公開日 2023-03-17
タイトル
タイトル Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
言語 en
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 Antiemetics
キーワード
言語 en
主題Scheme Other
主題 Antineoplastic Agents
キーワード
言語 en
主題Scheme Other
主題 Cisplatin
キーワード
言語 en
主題Scheme Other
主題 Dexamethasone
キーワード
言語 en
主題Scheme Other
主題 Female
キーワード
言語 en
主題Scheme Other
主題 Humans
キーワード
言語 en
主題Scheme Other
主題 Nausea
キーワード
言語 en
主題Scheme Other
主題 Retrospective Studies
キーワード
言語 en
主題Scheme Other
主題 Risk Factors
キーワード
言語 en
主題Scheme Other
主題 Uterine Cervical Neoplasms
キーワード
言語 en
主題Scheme Other
主題 Vomiting
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
抄録
値 Background/aim: Nausea and vomiting are two of the most distressing adverse events of cancer radiotherapy. The aim of this study was to examine the control rate and risk factors associated with nausea and vomiting in patients with cervical cancer receiving radiotherapy.

Patients and methods: This retrospective study examined patients with cervical cancer who received radiotherapy alone or with concomitant cisplatin. Patients who received radiotherapy alone were not administered antiemetic premedication, while patients who received radiotherapy with concomitant weekly cisplatin (40 mg/m2) were administered antiemetic therapy comprising granisetron and dexamethasone. Risk factors for non-complete response (CR) were identified using multivariate logistic regression analysis.

Results: Multivariate analysis indicated that younger age and concomitant weekly cisplatin were significant factors associated with non-CR across 5 weeks of treatment in patients who received radiotherapy. The proportion achieving CR among younger patients (<65 years) who received radiotherapy alone or with concomitant cisplatin was significantly lower than that among older patients (≥65 years) (Concomitant cisplatin: 27% vs. 67%, p=0.049; Radiotherapy alone: 62% vs. 91%, p=0.166). However, the proportion of patients achieving CR across 5 weeks of treatment was insufficient in all groups except for those aged ≥ 65 years who received radiotherapy alone.

Conclusion: Antiemetic prophylaxis should be considered for younger patients with cervical cancer undergoing radiotherapy alone. Further, neurokinin-1 receptor antagonist should be added to 5-hydroxytryptamine type-3 receptor antagonist and dexamethasone as antiemetic prophylactic therapy for patients with cervical cancer undergoing radiotherapy with concomitant weekly doses of 40 mg/m2 cisplatin.
書誌情報 en : Anticancer research

巻 42, 号 6, p. 3117-3123, 発行日 2022-06
DOI
値 10.21873/anticanres.15800
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-19 07:38:51.712207
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3